Oppenheimer Raises Price Target on Capricor Therapeutics (NASDAQ:CAPR) to $15.00

Capricor Therapeutics (NASDAQ:CAPR – Get a Free Report) had its price objective raised by research analysts at Oppenheimer from $14.00 to $15.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price objective would indicate a potential upside of 192.97% from the stock’s current price.

Several other analysts have also issued reports on CAPR. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Tuesday. Maxim Group reaffirmed a “buy” rating and set a $12.00 target price on shares of Capricor Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. The company has an average rating of “Moderate Buy” and a consensus price target of $20.00, according to MarketBeat.com.

Check out our latest research report on CAPR

Capricor Therapeutics stock rose 0.8%

NASDAQ:CAPR opened at $5.12 on Tuesday. Capricor Therapeutics has a twelve month low of $2.68 and a twelve month high of $7.28. The firm has a market cap of $163.73 million, a P/E ratio of -5.89 and a beta of 3.92. The company has a fifty day moving average of $4.35 and a 200 day moving average of $5.18.

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report ) last issued its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. The business had revenue of $3.97 million for the quarter, compared to analyst estimates of $4.51 million. On average, analysts anticipate that Capricor Therapeutics will post -1.24 EPS for the current fiscal year.

Hedge funds weigh in on Capricor Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CAPR. Jump Financial LLC bought a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $258,000. BNP Paribas Financial Markets bought a new stake in Capricor Therapeutics in the 1st quarter valued at approximately $40,000. Vanguard Group Inc. raised its position in Capricor Therapeutics by 17.2% in the first quarter. Vanguard Group Inc. now owns 1,365,903 shares of the biotechnology company’s stock worth $9,274,000 after buying an additional 200,499 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock valued at $381,000 after acquiring an additional 9,040 shares during the period. Finally, Rhumbline Advisers purchased a new stake in shares of Capricor Therapeutics in the second quarter valued at about $147,000. Hedge funds and other institutional investors own 21.68% of the company’s shares.

Capricor Therapeutics Company Profile

(Get a free report)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biologic therapies for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Featured stories

Receive daily news and ratings for Capricor Therapeutics – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Capricor Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.